Kidney Week 2018
October 23 – 28, 2018
Join ASN and more than 13,000 other kidney professionals from across the globe at Kidney Week 2018 in San Diego, CA. The world's premier nephrology meeting, Kidney Week provides participants exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field.
- August 29 - Early Registration Closes (11:59 p.m. EDT)
- September 5 - Late-Breaking Clinical Trial Submission Site Closes (2:00 p.m. EDT)
- September 21 - Housing Closes
- October 17 - Advance Registration Closes (11:59 p.m. EDT)
- October 18 - Late Registration Fees Begin
New this Year
ASN offers 10 Early Programs on Tuesday, October 23 and/or Wednesday, October 24, preceding the Annual Meeting (October 25-28). New offerings are:
- Advances in Research Conference: -Omics, Organoids, and Organs-on-Chips: Innovation Through Collaboration – Learn about critical recent advances in the biology of organoids and organs-on-chips as they relate to the human kidneys and how these in vitro systems can incorporate pharmacogenetics, gene expression profiles, multiple "-omics" technologies, and biomarker discovery and translation.
- Clinical Nephro-Pharmacology Across the Spectrum of Kidney Diseases – Gain up-to-date information on drug dosing, pharmacokinetics, and pharmacology in acute and chronic kidney diseases as well as RRT. Special focus is given to anticoagulants and the toxicity of cancer medications.
- Evaluation and Management of Kidney Stones – Explore the current state-of-the-art with the evaluation and management of all forms of stone disease. The role of stone imaging modalities is reviewed, including radiation risk. In addition, the indications, risks, and benefits of various surgical approaches for stone removal are presented
- Polycystic Kidney Disease: Translating Mechanisms into Therapy – Discover recent advances in understanding the pathophysiology and therapeutics for PKD. Experts discuss new strategies to assess risk for ADPKD progression, which will likely play a key role in identifying patients who may benefit from therapeutic interventions.